ISPE is pleased to announce the 2025 FOYA Submission Finalists that met the rigorous qualifications and requirements of the FOYA program.
The 2025 FOYA Category Winners will be announced in-person and virtually during the ISPE International Europe Annual Conference on 12 May 2025.
Amgen
Categories for consideration: Innovations, Operations
Location: New Albany, Ohio, USA
Project: Amgen Ohio (AOH)
As demand increased, Amgen's mission was to ensure continued, uninterrupted supply of critical medicines; every patient every time. Amgen Ohio (AOH) will fulfill that commitment and drive value for patients through best-in-class efficiencies and sustainability of their most technologically advanced assembly and packaging facility.
Bayer Healthcare LLC
Categories for consideration: Innovation, Operations, Supply Chain, Pharma 4.0™, Social Impact
Location: Berkeley, California, USA
Project: Cell Therapy Launch and Manufacturing Facility
Bayer Healthcare LLC's Cell Therapy Launch and Manufacturing Facility, driven by the mission "For the Patient," prioritized leadership, integrity, flexibility, and efficiency. The project aimed to rapidly deliver meaningful treatments by designing, constructing, and qualifying a facility for Bayer's technology continuum, ensuring safety, cost-effectiveness, timely completion, and strong partner relationships.
BioNTech SE
Categories for consideration: Social Impact
Location: Marburg, Germany
Project: BioNTainer
BioNTech SE's BioNTainer project delivers a transformative approach to mRNA production through modular, scalable facilities. This initiative seeks to strengthen global vaccine supply chains, bolster preparedness for epidemics and pandemics, and expand the applications of mRNA technology in research and development.
CSL Behring
Categories for consideration: Innovation, Operations, Social Impact
Location: Broadmeadows, Victoria, Australia
Project: Project Aurora - Facility F Base Fractionation
Project Aurora is dedicated to advancing global healthcare through the establishment of the world's largest Plasma Base Fractionation Facility at CSL's Broadmeadows campus. Their key goals include increase plasma processing capacity, enhance operational efficiency, sustainability, support global healthcare needs, foster human connections, economic and community impact and allow for future expansion. These goals collectively aim to enhance CSL's capacity to deliver innovative and life-saving therapies while maintaining a strong commitment to sustainability and community impact.
Erbe Elektromedizin GmbH
Categories for consideration: Innovation, Social Impact
Location: Rangendingen, Germany
Project: Erbe 4.i
Erbe Elektromedizin GmbH's Erbe 4.i competence center prioritizes both sustainability and efficient collaboration. By consolidating all company functions—from product development and prototype manufacturing to commercial manufacturing and administration—it enables streamlined end-to-end exchange from R&D to customer training. This building project represents a milestone in sustainable industrial construction in Germany, combining ecological, economic, and social sustainability aspects.
F. Hoffmann-LaRoche AG
Categories for consideration: Innovation, Social Impact
Location: Basel, Switzerland
Project: pRED Innovation Center
The pRED Innovation Center at the Roche headquarters in Basel is a state-of-the-art research center dedicated to the discovery and development of groundbreaking drugs. It replaces the aging research and development buildings that could no longer be adapted to the latest requirements. The need to renew this infrastructure gave Roche the opportunity to set new standards in health science architecture. The pRED Innovation Center offers 1,800 researchers from various disciplines an inspiring working environment that facilitates communication and collaboration. Flexibility to adapt to the changing requirements of interdisciplinary collaboration while taking advantage of the numerous possibilities of digitalization have been central goals together with enhancing communication and collaboration for people to connect and exchange ideas.
Grünenthal
Categories for consideration: Operations
Location: Penalolen, Chile
Project: Master Program LatAm Kairos
Grünenthal’s project Master Program LatAm Kairos located in Penalolen, Chile transformed a local manufacturing site to a world-class operations facility for solids forms. Their mission was focused on supplying safe, efficient, and reliable medicines to patients.
Johnson & Johnson Innovative Medicine
Categories for consideration: Innovation, Operations, Pharma 4.0™
Location: Latina, Italy
Project: Flexible Bottle Packaging Line
Johnson & Johnson Innovative Medicine's Flexible Bottle Packaging Line project in Latina, Italy aimed to drastically reduce changeover times for small-batch production. By implementing a new flexible packaging line and an optimized organizational model, the project successfully shortened changeover from six hours to a mere 45 minutes, significantly enhancing efficiency.
Johnson & Johnson Innovative Medicine
Categories for consideration: Innovation, Operations, Pharma 4.0™
Location: Sassenheim, The Netherlands
Project: Pollux
Project Pollux is a schedule-driven project that has delivered a Lentiviral Vector (LVV) production hub for the Johnson & Johnson Innovative Medicine Advanced Therapies CAR-T global supply chain. The design of the facility is inherent flexible, allowing for multi-product production capabilities and the ability to scale up or scale out the LVV process depending on future business and new product needs. Key attributes for this project include delivery of LVV in a reliable manner, transforming a laboratory-type production operation into a commercial comparable process through the use of fixed process skids per unit operation, standardizing the production operations to reduce the level of human intervention, and utilizing digital technologies including MES in a paperless plant environment by deploying electronic batch records.
Johnson & Johnson Innovative Medicine
Categories for consideration: Innovation, Operations, Supply Chain, Social Impact
Location: Ringaskiddy, Cork, Ireland
Project: BioCork 3.2 Expansion Project
Johnson & Johnson Innovative Medicine’s mission with the BioCork 3.2 Expansion project in Cork, Ireland was to ensure that they met the needs of their patients today and into the future. To achieve this, they expanded their capabilities with the addition of three large-scale (15,000 litre) production bioreactors, enabling the efficient and sustainable delivery of innovative products. This expansion was designed to fully integrate into their existing live manufacturing plant without disrupting current operations. This investment increased the manufacturing capacity by 80% within budget and ahead of schedule.
Kindeva Drug Delivery
Categories for consideration: Operations
Location: Bridgeton, Missouri, USA
Project: Kindeva Bridgeton
To address the pharmaceutical industry's growing needs, Kindeva Drug Delivery realized its future-forward vision in 2023 with Project Kindeva Bridgeton, a state-of-the-art aseptic injectable fill-finish facility built in record time in Bridgeton, Missouri.
Nitto Denko Avecia
Categories for consideration: Innovation, Supply Chain
Location: Milford, Massachusetts, USA
Project: Project M5
To meet the growing clinical and commercial demand for oligonucleotides, Nitto Denko Avecia's Project M5 in Milford, Massachusetts, USA delivered an integrated contract manufacturing facility designed for long-term growth and sustainability.
Oncomed Manufacturing A.S.
Categories for consideration: Innovation, Operations
Location: Brno, Czech Republic
Project: Syringe Line 3 Installation and Facility Modernization
To modernize its production capabilities, Oncomed Manufacturing A.S. implemented the Syringe Line 3 Installation and Facility Modernization project. This initiative introduced new syringe technology, revamped the production building, and established centralized workstations. The project aimed to achieve a 100 million syringe annual production capacity, increase material and solution preparation efficiency, and enhance safety in handling hazardous materials.
Sanofi
Categories for consideration: Social Impact
Location: Toronto, Ontario, Canada
Project: Building 99 - Wastewater Treatment and Recovery Plant (WWTRP)
To achieve its own "planet care" targets and ensure long-term site investment, Sanofi constructed the Building 99 - Wastewater Treatment and Recovery Plant (WWTRP). This plant minimizes domestic water usage through waste recycling, ensures regulatory-compliant effluent discharge, and provides an environmental buffer that enables sustainable site growth.
Takeda Pharmaceutical Company Limited
Categories for consideration: Operations
Location: Tokyo, Japan
Project: Enoshima Light House
Takeda Pharmaceutical Company Limited's Enoshima Light House project in Tokya, Japan aimed to establish a state-of-the-art GMP manufacturing facility within an existing research building, supporting the process development and production of biologics for first-in-human clinical trials. The project prioritized high standards of safety, sustainability, and environmental responsibility.
Touchlight
Categories for consideration: Innovation, Operations, Supply Chain, Social Impact
Location: Hampton, London, UK
Project: Development and Manufacture of Novel Synthetic DNA to Enable the Future of Genetic Medicines
Touchlight's project, Development and Manufacture of Novel Synthetic DNA to Enable the Future of Genetic Medicines, established a GMP manufacturing facility for its proprietary doggybone DNA platform. This facility, designed to meet the growing demand for genetic medicines, consolidates CDMO-related staff in dedicated office space and have successfully obtained regulatory approval as an enzymatic DNA facility and scaling production to a commercial level, positioning it as one of the world’s largest DNA manufacturing sites.
United Therapeutics
Categories for consideration: Innovation & Social Impact
Location: Christiansburg, Virginia, USA
Project: Clinical Xenotransplantation DPF Facility
To revolutionize organ transplantation and overcome the critical shortage of human organs, United Therapeutics initiated the Clinical Xenotransplantation DPF Facility project, focused on creating an unlimited supply of tolerable transplantable organs via xenotransplantation.